Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines by Veselska, Renata et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Nestin expression in osteosarcomas and derivation of nestin/CD133 
positive osteosarcoma cell lines
Renata Veselska*1,2, Marketa Hermanova3,4, Tomas Loja1, Petr Chlapek1, 
Iva Zambo3,4, Karel Vesely3, Karel Zitterbart2 and Jaroslav Sterba2
Address: 1Laboratory of Tumor Biology and Genetics, Institute of Experimental Biology, School of Science, Masaryk University, Kotlarska 2, 611 
37 Brno, Czech Republic, 2Department of Pediatric Oncology, University Hospital Brno, Cernopolni 9, 613 00 Brno, Czech Republic, 31st Institute 
of Pathologic Anatomy, St. Anne's University Hospital, Pekarska 53, 656 91 Brno, Czech Republic and 4Institute of Pathology, University Hospital 
Brno, Jihlavska 20, 625 00 Brno, Czech Republic
Email: Renata Veselska* - veselska@sci.muni.cz; Marketa Hermanova - marketa.hermanova@fnusa.cz; Tomas Loja - tloja@sci.muni.cz; 
Petr Chlapek - muscari@mail.muni.cz; Iva Zambo - iva.zambo@fnusa.cz; Karel Vesely - karel.vesely@fnusa.cz; 
Karel Zitterbart - kzitterbart@fnbrno.cz; Jaroslav Sterba - jsterb@fnbrno.cz
* Corresponding author    
Abstract
Background: Nestin was originally identified as a class VI intermediate filament protein that is
expressed in stem cells and progenitor cells in the mammalian CNS during development. This
protein is replaced in the adult organism by other intermediate filament proteins; however, nestin
may be re-expressed under certain pathological conditions such as ischemia, inflammation, brain
injury, and neoplastic transformation. Nestin has been detected in many kinds of tumors, especially
in tumors derived from the CNS. Co-expression of nestin and the CD133 surface molecule is
considered to be a marker for cancer stem cells in neurogenic tumors. Our work was aimed at a
detailed study of nestin expression in osteosarcomas and osteosarcoma-derived cell lines.
Methods: Using immunodetection methods, we examined nestin in tumor tissue samples from 18
patients with osteosarcomas. We also successfully established permanent cell lines from the tumor
tissue of 4 patients and immunodetection of nestin and CD133 was performed on these cell lines.
Results: Nestin-positive tumor cells were immunohistochemically detected in all of the examined
osteosarcomas, but the proportion of these cells that were positively stained as well as the intensity
of staining varied. Nestin-positive cells were rarely observed in 2 tumor samples, and the remaining
16 tumor samples showed various nestin expression patterns ranging from very sporadic
occurrence to an overwhelming proportion of cells with strong positive staining. Three of the
established osteosarcoma cell lines were demonstrated to be nestin-positive, and only one cell line
showed no expression of nestin; this finding corresponds with the rare occurrence of nestin-
positive cells in the respective tumor sample. Moreover, three of these osteosarcoma cell lines
were undoubtedly proven to be Nes+/CD133+.
Conclusion: Our results represent the first evidence of nestin expression in osteosarcomas and
suggest the possible occurrence of cells with a stem-like phenotype in these tumors.
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Background
Nestin, a neural stem cell protein, was identified as a class
VI intermediate filament protein. The molecule consists of
1,618 amino acids and its molecular weight is 176 kDa [1-
3]; the nestin gene contains 4 exons and 3 introns [4].
Nestin expression has been shown in proliferating neu-
roepithelium during the development of the mammalian
CNS, as well as in both human and rodent neural stem
cells in vivo [5-7]. Nestin was also expressed in various
immortalized mammalian stem cell lines and precursor
cell lines [8]. In the adult CNS, nestin is detectable only in
the stem cells of the subventricular zone and in the
choroid plexus [7]. Re-expression of downregulated nes-
tin was reported in reactive astrocytes following certain
types of brain injuries, as well as in reactive astrocytes and
endothelial cells in cerebral abscesses [9,10].
Immunodetection has shown that nestin is expressed in
many kinds of tumors, especially in tumors derived from
CNS (e.g., central neurocytomas, gangliogliomas, epend-
ymomas, pilocytic astrocytomas, high-grade gliomas
including glioblastoma multiforme), and embryonal
tumors originating from the CNS (primitive neuroecto-
dermal tumors – PNETs, medulloblastomas, and medul-
loepitheliomas) [5,11-24]. Nevertheless, nestin
expression was also detected in rhabdomyosarcomas [25],
gastrointestinal stromal tumors (GISTs) [26-29], malig-
nant melanomas [30,31], hepatocellular carcinomas, cer-
vical carcinomas, and ovarian carcinomas [32]. Its
occurrence in tumor cells is not limited to the cytoplasm
only; nestin localization in cell nuclei was clearly con-
firmed in some neuroblastoma and glioblastoma cell
lines [33,34]. Coexpression of nestin and CD133 (also
known as prominin-1) is considered to be a marker for
cancer stem cells (CSCs); this fact was experimentally
proven in glioblastoma multiforme and malignant
melanoma [31,35,36].
The present study was aimed at the examination of nestin
in tumor tissue samples taken from patients with osteosa-
rcomas and in cell lines derived from these tumors using
immunohistochemistry and immunofluorescence. Nes-
tin-positive (Nes+) tumor cells were detected in all of
them, but the proportion of the cells that expressed nestin
as well as the intensity of the staining varied from a rare
occurrence of Nes+ cells to an overwhelming proportion
of cells with high nestin expression. We also successfully
derived permanent cell lines from the tumor tissues of
four patients with osteosarcoma and three of these cell
lines were undoubtedly proven to be Nes+/CD133+. Our
results represent the first evidence of nestin expression in
osteosarcomas and suggest the possible occurrence of cells
with stem-like phenotype in these tumors.
Methods
Tumor samples
Eighteen samples of primary untreated high-grade oste-
osarcoma of bone (17 conventional osteosarcomas: 15
osteoblastic and 2 chondroblastic, and 1 telangiectatic
osteosarcoma; 9 males, 9 females; age range: 8–57 years
old, mean 21 years old) were included in this study. For-
malin-fixed and paraffin-embedded surgical samples of
neoplastic tissues were retrieved from the files of the
Department of Pathology, University Hospital Brno,
Czech Republic, and of the 1st Department of Pathologic
Anatomy, St. Anne's University Hospital, Brno, Czech
Republic. The histologic sections stained with H-E were
reviewed by three pathologists in total and each individ-
ual tumor sample by two of them (MH and IZ; or MH and
KV), and representative tissue blocks were selected for
immunohistochemical analysis. Fifteen samples were not
ossified and were not subjected to decalcification and
three cases were decalcified using 8% hydrochloride acid-
ferric chloride solution, as indicated in the Table 1. To
obtain cell cultures, biopsy samples were taken from 4
patients surgically treated for osteosarcoma. Written
informed consent was obtained from each participant
before entering into this study. The samples for cell cul-
tures were coded and processed in the laboratory in an
anonymous manner. The Research Ethics Committee of
the University Hospital Brno approved the study protocol.
Immunohistochemistry
Immunohistochemical detection of nestin was performed
on 4 μm thick tissue sections applied to positively-
charged slides. The sections were deparaffinized in xylene
and rehydrated through a graded alcohol series. Antigen
retrieval was performed in the lab microwave (Milestone)
by heating the sections in citrate buffer at pH 6.0 for 20
min at 98°C. Endogenous peroxidase activity was
quenched in 3% hydrogen peroxide in methanol for 10
minutes. Tissue sections were incubated overnight at 4°C
with a mouse monoclonal antibody to nestin (clone
10C2, dilution 1:200, Millipore, Billerica, MA, USA). A
streptavidin-biotin peroxidase detection system was used
in accordance with the manufacturer's instructions
(Vectastain Elite Kit, Vector Laboratories, Burlingame, CA,
USA); 3,3'-diaminobenzidine was used as the chromogen
(DAB, Fluca, USA). Slides were counterstained with Gill's
hematoxylin. Tissue sections of glioblastoma multiforme
served as external positive controls; nestin-positive
endothelial cells in osteosarcoma tissue samples were
used as internal positive controls. Negative controls were
prepared by incubating samples without the primary anti-
body. Evaluation of immunohistochemical results was
performed using a uniform microscope and camera set-
ting (Olympus BX51, DP70).BMC Cancer 2008, 8:300 http://www.biomedcentral.com/1471-2407/8/300
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Evaluation of immunohistochemistry
For nestin, cytoplasmic immunostaining was considered
to be positive. The percentage of Nes+ tumor cells (TC)
was counted and categorized into four levels: +/- (<2 %
Nes+ TC), + (2–10 % Nes+ TC), ++ (11–50 % Nes+ TC),
and +++ (51–100 % Nes+ TC). The intensity of immunos-
taining was classified as very weak (+/-), weak (+),
medium (++), and strong (+++). The intensity of immu-
nostaining was also evaluated in endothelial cells, which
were used as an internal positive control. The slides were
evaluated with a light microscope at ×400 magnification.
At least 5 discrete foci of neoplastic infiltration were ana-
lyzed, and the average staining intensity and the percent-
age of nestin positive cells of the entire covered area were
determined.
Cell cultures
Starting with primary cultures, fresh specimens of tumor
tissue were processed as described previously [34]. The
primary cultures were maintained in DMEM supple-
mented with 20% fetal calf serum, 2 mM glutamine, and
antibiotics: 100 IU/ml of penicillin and 100 μg/ml of
streptomycin (all purchased from PAA Laboratories, Linz,
Austria) and cultivated under standard conditions at
37°C in an atmosphere of 95% air : 5% CO2. Once the
specimen pieces had attached, the volume of the medium
was gradually increased to 5 ml over the next 48 hours. As
soon as the outgrowing cells covered about 60% of the
surface, they were trypsinized, diluted, and transferred
into a new flask. A similar procedure was used for further
subcultivations of all cell lines that were derived from the
primary cultures. Altogether, 4 successfully derived oste-
osarcoma cell lines (OSA-1, OSA-2, OSA-3, and OSA-5)
were included in this study. The basic description (gender
and age) of the patients from whom the respective sam-
ples were taken is given in the Table 1. The established
Saos-2 osteosarcoma cell line (ATCC No. HTB-85) and the
GM-7 glioblastoma cell line [34] were used as control cell
lines in this study.
Immunofluorescence
To perform immunostaining of intracellular and cell sur-
face antigens in these cell lines, cell suspensions at a con-
centration of 104  cells per ml were seeded on glass
coverslips and grown under standard conditions for 24 h.
Cells were then washed in PBS, fixed with 3% para-for-
maldehyde (Sigma) in PBS for 20 min at RT, and permea-
bilized with 0.2% Triton X-100 (INC Biomedicals) in PBS
for 1 min at RT. For detection of the CD133 cell surface
molecule, this procedure was performed without permea-
bilization. The cells were subsequently washed in PBS and
incubated for 10 min with 2% BSA (PAA) to block non-
specific binding of the secondary antibodies. All intracel-
lular and cell surface antigens were visualized by indirect
immunofluorescence. Mouse monoclonal human-spe-
cific anti-nestin antibody (clone 10C2, dilution 1:200,
Millipore), mouse monoclonal anti-vimentin antibody
(clone LN-6, dilution 1:100, Sigma Chemical Co., St.
Louis, MO, USA), mouse monoclonal anti-desmin anti-
body (clone DE-U-10, dilution 1:40, Sigma), rabbit poly-
clonal anti-S100 antibody (No. S2644, working
concentration 20 μg.ml-1, Sigma), and rabbit polyclonal
anti-CD133 antibody (No. ab19898, dilution 1:100,
Abcam, Cambridge, UK) were used as primary antibodies.
The cells were treated with primary antibodies at 37°C for
1 h and then washed three times in PBS. Corresponding
secondary antibodies, i.e. anti-mouse antibodies conju-
gated with FITC or TRITC (Sigma) or anti-rabbit antibody
conjugated with TRITC (Sigma), were applied under the
same conditions. Finally, the cells were mounted onto
glass slides in Vectashield mounting medium containing
DAPI (Vector Laboratories, Burlingame, CA, USA). The
cells were observed using an Olympus BX-61 fluorescence
microscope. Micrographs were captured with a CCD cam-
era COHU 4910 and analyzed using software Lucia 4.80 –
KARYO/FISH/CGH (Laboratory Imaging, Prague, Czech
Republic).
Results
Nestin detection in the osteosarcoma tumor tissue
The results of the immunohistochemical detection of nes-
tin expression in osteosarcomas are summarized in Table
1. Nes+ tumor cells were found in all examined tumor
samples taken from the 18 patients of both gender and
various age (Figure 1a–c). Nevertheless, the frequency of
these Nes+ cells ranged from the strong positivity in a sig-
nificant proportion of tumor cells (Table 1, Figure 1a),
through a dispersed distribution (Table 1, Figure 1b), to a
sporadic occurrence of these cells (Table 1, Figure 1c).
Similarly, the intensity of immunostaining for nestin var-
ied from strong to very weak (Table 1, Figure 1a–c). All 18
tumor samples undoubtedly showed Nes+ endothelial
cells.
Expression of nestin and CD133 in osteosarcoma cell lines
Immunoreactivity for nestin was examined in four newly
derived osteosarcoma cell lines as described above. In the
way of other intracellular markers, all of these cell lines
were positive for vimentin (Figure 2a), desmin (Figure
2b), and S100 protein (Figure 2c). Results concerning the
immunoreactivity for nestin, CD133 and other intracellu-
lar proteins are summarized in Table 2. Nestin was
detected in three (OSA-1, OSA-2, and OSA-3) of the four
examined cell lines; in the OSA-5 cell line no signal for
nestin was observed (Table 2, Figure 2k–l). The OSA-3 cell
line displayed a strong, even positivity for nestin and a
distinct network of Nes+ filaments in the cytoplasm of
individual cells (Figure 2h–i), while OSA-1 and OSA-2
cell lines showed medium intensity of fluorescence, and
only the diffuse signal in the cytoplasm was observable.BMC Cancer 2008, 8:300 http://www.biomedcentral.com/1471-2407/8/300
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All newly derived cell lines also showed a strong positivity
for the CD133 membrane antigen (Figure 2g,i), including
the nestin-negative OSA-5 cell line (Figure 2j,l). Double-
labeling of both of these antigens confirmed their appear-
ance in the same cells (Figure 2g–i). Control Saos-2 oste-
osarcoma cell line also clearly showed both of nestin
(Figure 2e) and CD133 (Figure 2f) positivity.
Discussion
Our research was primarily focused on the examination of
possible nestin expression in osteosarcoma tissue sections
using immunohistochemistry. Obtained results clearly
confirmed the presence of Nes+ tumor cells in samples
taken from all patients involved in the study, although the
frequency of Nes+ cells as well as the immunoreactivity
varied in the individual samples. Nevertheless, our
research produced the first evidence of nestin expression
in the osteosarcomas.
Although the nestin was detected in many kinds of solid
tumors, its expression is widely recognized as a tumor
marker especially of malignancies of neuroectodermal
origin [5,11-24]. For other tumors, nestin expression was
still reported in GISTs [26-29], malignant melanomas
[30,31], hepatocellular carcinomas, cervical carcinomas,
and ovarian carcinomas [32]. However, there is only a
minimum of similar findings in soft tissue sarcomas; the
only one evidence of nestin was given in pediatric rhab-
domyosarcomas [25] and angiosarcomas [37]. In synovial
sarcomas, nestin expression was documented in approxi-
mately 10% of pediatric synovial sarcomas [38] but it was
not detected in the same tumor type in another study [39].
Not very surprisingly, nestin expression was also sporadi-
cally showed in Ewing sarcomas/PNETs [39].
To verify our findings in osteosarcoma tissue sections
stained by IHC, we used four cell lines that were newly
derived from osteosarcomas in our laboratory. The results
obtained from these cell lines by indirect immunofluores-
cence clearly confirmed the findings on the corresponding
tissue sections. All three Nes+ cell lines showing the
medium (OSA-01 and OSA-02 cell lines) or strong (OSA-
03 cell line) expression of nestin were derived from the
tumors containing cells with medium or strong nestin
positivity (Table 1), although the frequency of these Nes+
cells varied in the individual tumors (Figure 1). The OSA-
05 cell line was repeatedly demonstrated as nestin-nega-
tive during the long-term cultivation at different passages,
and this cell line was derived from the only telangiectatic
osteosarcoma, in which the only rare occurrence of Nes+
cells was demonstrated. The validity of these results using
newly derived osteosarcoma cell lines was clearly con-
firmed by immunodetection of the strong nestin positiv-
ity also in the established Saos-2 cell line that was used as
a control osteosarcoma cell line in our study.
Table 1: Immunohistochemical analysis of nestin expression in osteosarcomas
Sample Gender Age Tumor type Nestin Cell line
% TC IR TC IR EC
1F8 C - O S - O B / D C + + + + +
2 F 14 C-OS-OB + +/- +/-
3 F 56 C-OS-OB + + +/-
4 M 57 C-OS-OB + +/- +/-
5 F 18 C-OS-OB + +/- +/-
6M 1 5 C - O S - O B + + + + +
7 M 15 C-OS-OB + + +/-
8 F 23 C-OS-CB/DC + + +
9 M 21 C-OS-CB/DC + +/- +/-
10 F 14 C-OS-OB +/- +/- +/-
11 F 13 C-OS-OB + ++ ++ OSA-01
12 F 19 C-OS-OB + + ++
13 M 21 C-OS-OB +++ +++ ++
14 M 15 C-OS-OB ++ ++ +
15 F 28 C-OS-OB ++ + +/-
16 M 21 C-OS-OB +++ +++ ++ OSA-02
17 M 15 C-OS-OB ++ ++ ++ OSA-03
18 M 9 OS-TAE +/- + + OSA-05
Expression of nestin was examined on formalin-fixed, paraffin-embedded tissue specimens of osteosarcomas using immunohistochemistry. % TC, 
percentage of nestin positive tumor cells (+/-, <2 %; +, 2–10 %; ++, 11–50 %; +++, 51–100 %). IR TC, intensity of immunostaining 
(immunoreactivity) in tumor cells (+/-, very weak; +, weak; ++, medium; +++, strong). IR EC, intensity of immunostaining (immunoreactivity) in 
endothelial cells (+/-, very weak; +, weak; ++, medium; +++, strong). Tumor type: C-OS-OB, high grade conventional osteosarcoma, osteoblastic; 
OS-TAE, teleangiectatic osteosarcoma; C-OS-CB, high grade conventional osteosarcoma, chondroblastic; DC, decalcified.BMC Cancer 2008, 8:300 http://www.biomedcentral.com/1471-2407/8/300
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In regard to the recently reported expression of CSCs
marker CD133 in Saos-2 cell line cell [40], we also inves-
tigated our new osteosarcoma cell lines for this cell surface
antigen. The results clearly showed the expression of this
CSCs marker in all four examined cell lines. CD133
expression was strong in two of three Nes+ cell lines
(OSA-02, and OSA-03) as well as in the control Saos-2 cell
line, whereas medium immunoreactivity was detected in
Nes+ OSA-01 cell line and in nestin-negative OSA-5 cell
line.
CSCs from different histogenetic categories of tumors may
vary in their pattern of specific markers; nevertheless,
common phenotypic characteristics of leukemia, brain
tumors, prostate cancer, lung carcinoma, malignant
melanoma, head and neck squamous cell carcinoma, and
breast cancer CSCs are known [41-44]. Co-expression of
nestin and CD133 was previously recognized to be a typ-
ical characteristic of CSCs in CNS tumors [35], but it was
found also in other tumors of ectodermal origin [31]. At
present, expression of CD133 is considered to be a univer-
sal marker of CSCs also in other histogenetic types of
tumors [43,45]. Our results regarding the co-expression of
CD133 and nestin in newly derived osteosarcoma cell
lines as well as in the established Saos-2 cell line suggest
the presence of cells with CSCs characteristics also in oste-
osarcomas.
Biological features of CSCs and their occurrence in various
types of malignancies are undoubtedly one of the topical
issues in up-to-date cancer research. CSCs seem to play a
key role in tumor initiation, progression, and metastasis
[43,46], and they may thus represent an important target
in anticancer treatment [41].
Our results concerning the first evidence of nestin expres-
sion in osteosarcomas, some previously reported findings
on nestin expression in soft-tissue sarcomas [25,37,38],
and particularly our detection of CSCs features in osteosa-
rcoma-derived cell lines indicate the importance of such
research with regard to the bone and soft-tissue sarcomas.
Therefore, the present study is a first step to further
detailed investigation of the cells exhibiting CSCs markers
in osteosarcoma tumor tissue, especially in view of the
clinical course of the disease.
Conclusion
The most important result of our study is the first evidence
of nestin expression in osteosarcomas. To summarize,
nestin-positive tumor cells were immunohistochemically
detected in all of the examined osteosarcomas, although
the proportion of Nes+ cells as well as the intensity of
staining varied. Three of the established osteosarcoma cell
lines were demonstrated to be nestin-positive, and only
one cell line showed no expression of nestin. These find-
ings correspond with the rare occurrence of Nes+ cells in
the respective tumor sample. Moreover, three of these
lines as well as the control Saos-2 osteosarcoma cell line
were undoubtedly proven to be Nes+/CD133+. This
important finding suggests the possible occurrence of cells
with a stem-like phenotype in osteosarcomas.
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BSA: bovine serum albumin; C-OS-CB: high grade con-
ventional osteosarcoma, chondroblastic; C-OS-OB: high
grade conventional osteosarcoma, osteoblastic; CSCs:
cancer stem cells; DAPI: 4,6-diamidino-2-phenylindol;
DC: decalcified; DMEM: Dulbecco's modified Eagle's
medium; EC: endothelial cells; FITC: fluorescein isothio-
cyanate; GISTs: gastrointestinal stromal tumors; H-E:
hematoxylin-eosin; IHC: immunohistochemistry; IR:
Immunohistochemical analysis of nestin expression in con- ventional osteosarcomas Figure 1
Immunohistochemical analysis of nestin expression 
in conventional osteosarcomas. Strong diffuse cytoplas-
mic nestin immunostaining in majority of tumor cells; sample 
16 (a). Strong cytoplasmic nestin immunostaining in a subset 
of tumor cells; sample 11 (b). Medium to strong cytoplasmic 
nestin expression in a minority of tumor cells dispersedly; 
sample 17 (c). Glioblastoma multiforme was used as a posi-
tive control (d). Immunoperoxidase with Gill's hematoxylin 
counterstain. Bars, 100 μm.BMC Cancer 2008, 8:300 http://www.biomedcentral.com/1471-2407/8/300
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Figure 2 
Expression of nestin, CD133 and other intracellular proteins in the osteosarcoma cell lines. Representative 
expression of vimentin, desmin, and S100 protein in the osteosarcoma cell lines: vimentin expression in OSA-03 cell line (a); 
desmin expression in OSA-02 cell line (b); S100 protein expression in OSA-01 cell line (c). Medium or strong expression of 
nestin was found in three newly derived cell lines and the distinct network of nestin-positive filaments was observable in the 
OSA-03 cell line (h, i). OSA-05 cell line was nestin-negative (k, l). Expression of CD133 cell surface molecule (g, i, j, l) was 
found in all osteosarcoma cell lines and co-expression of nestin and CD133 was confirmed using double labeling in nestin-pos-
itive cell lines (g-i). Representative double labeling for CD133 and nestin in nestin-positive OSA-03 (g-i) and nestin-negative 
OSA-05 (j-l) newly derived osteosarcoma cell lines. Glioblastoma GM-7 cell line labeled by the same antibodies was used as 
positive control (d) and control established Saos-2 osteosarcoma cell line also showed strong positivity for both nestin (e) and 
CD133 (f). Vimentin (a, red), S100 protein (c, red), and CD133 (d, f, g, i, j, l, red) stained by indirect immunofluorescence using 
TRITC-labeled secondary antibody; desmin (b, green) and nestin (d, e, h, i, k, l, green) stained by the same method using FITC-
labeled secondary antibody; counterstaining with DAPI (a-f, i, l). Bars, 30 μm (a-c), 20 μm (d), 15 μm (e-l).BMC Cancer 2008, 8:300 http://www.biomedcentral.com/1471-2407/8/300
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immunoreactivity; Nes+: nestin positive; OS-TAE: tel-
angiectatic osteosarcoma; PBS: phosphate-buffered saline;
PNETs: primitive neuroectodermal tumors; RT: room tem-
perature; TC: tumor cells; TRITC: tetramethylrhodamine
isothiocyanate.
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